RxDoctor Payments Data

Wesley Henson

Nurse Practitioner · Mc Leansboro, ILNPI 1235380155

Payments from drug & device makers

$5,865in general payments, 2019–2025

Across 271 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$790
  • AbbVie$701
  • Lilly USA, LLC$676
  • Novo Nordisk$587
  • GSK$473
  • plus $803 from 20 others

What the payments were for

  • Food & beverage$5,865100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,865 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$1,170
Medicare patients
73
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide112$127,160
OtezlaApremilast26$121,583
FarxigaDapagliflozin Propanediol101$72,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter106$71,176
OzempicSemaglutide61$56,348
EliquisApixaban70$54,605
JardianceEmpagliflozin52$51,917
XareltoRivaroxaban38$36,997
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$31,500
TrulicityDulaglutide27$25,692
LinzessLinaclotide28$24,214
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$21,468
Tresiba Flextouch U-200Insulin Degludec11$20,573
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$12,620
Repatha SureclickEvolocumab16$8,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$676$152,852139 claims
AmgenOtezla$790$121,58326 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,836$107,606164 claims
GSKTrelegy Ellipta$473$71,176106 claims
Novo NordiskOzempic$587$56,34861 claims
PfizerEliquis$58$54,60570 claims
Boehringer IngelheimJardiance$33$51,91752 claims
AbbVieLinzess, Synthroid$701$25,95165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Mc Leansboro

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →